{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-056048","form_type":"8-K","ticker":"SABS","cik":"0001833214","company_name":"SAB Biotherapeutics, Inc.","filed_at":"2023-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.869504+00:00","generated_at":"2026-06-09T07:15:16.937915+00:00","sec_items":["1.01","5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Appoints Michael King as CFO with $450K salary and 850K share option grant","bullets":["Michael King appointed CFO effective Oct 30, 2023; Russell Beyer ceased as CFO on Oct 27.","Base salary $450,000, target annual bonus of 40% of base, and 850,000 stock options.","Options vest over 4 years: 25% on 1-year anniversary, then monthly over 36 months.","King has 25+ years in biotech research; most recently Co-Head of Healthcare at EF Hutton.","No family relationships or arrangements with others influenced his selection."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-056048","json":"https://secwatch.observer/filing/0000950170-23-056048.json","markdown":"https://secwatch.observer/filing/0000950170-23-056048.md","text":"https://secwatch.observer/filing/0000950170-23-056048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833214/000095017023056048/0000950170-23-056048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833214/000095017023056048/sabs-20231023.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T07:15:16.937915+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"12e3ad179e","claim":"Michael King was appointed as Chief Financial Officer at SAB Biotherapeutics, Inc..","evidence_excerpt":"Michael King, age 62, was appointed Chief Financial Officer of SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”), effective October 30, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017023056048/0000950170-23-056048-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"e6b61614f8","claim":"Russell P. Beyer departed as Chief Financial Officer at SAB Biotherapeutics, Inc..","evidence_excerpt":"Russell P. Beyer ceased to serve as Chief Financial Officer of the Company on October 27, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017023056048/0000950170-23-056048-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}